newsfilter
← Latest News
GlobeNewswire·

Immatics Announces First Quarter 2026 Financial Results and Business Update

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company's first commercial launch planned in 2027Multiple key clinical data sets